Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (0.5 mg to 200 mg) of BI 14332 CL as Powder in the Bottle Reconstituted With 0.1% Tartaric Acid Administered to Healthy Male Subjects. A Randomised and Placebo-controlled Trial, Double Blinded Within Dose Groups

NCT02211989 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02211989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02211989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (0.5 mg to 200 mg) of BI 14332 CL as Powder in the Bottle Reconstituted With 0.1% Tartaric Acid Administered to Healthy Male Subjects. A Randomised and Placebo-controlled Trial, Double Blinded Within Dose Groups
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2006
Completion date
Not reported
Enrollment
53 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy